Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.40 |
| ▸ | EP300 | Q09472 | 3/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | POLG | P54098 | 1/20 | 0.30 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26803955 | 0.85 | FGFR1 (0.65) | FGFR1STING1EP300HPRT1 | |
| SCHEMBL14510063 | 0.83 | FGFR1 (0.56) | FGFR1EP300ADRB1DNMT1HPRT1 | |
| SCHEMBL14510064 | 0.82 | FGFR1 (0.54) | FGFR1ADRB1DNMT1HPRT1 | |
| SCHEMBL1135969 | 0.81 | FGFR1 (0.50) | FGFR1EP300ADRB1DNMT1HPRT1 | |
| SCHEMBL1105217 | 0.81 | FGFR1 (0.44) | FGFR1HPRT1 | |
| SCHEMBL1105222 | 0.79 | FGFR1 (0.73) | FGFR1EP300ADRB1DNMT1 | |
| SCHEMBL20644347 | 0.78 | FGFR1 (0.54) | FGFR1 | |
| SCHEMBL1094931 | 0.77 | FGFR1 (0.53) | FGFR1EP300ADRB1DNMT1HPRT1 | |
| SCHEMBL1105218 | 0.76 | FGFR1 (0.49) | FGFR1ADRB1DNMT1HPRT1 | |
| SCHEMBL1094927 | 0.76 | FGFR1 (0.67) | FGFR1ADRB1DNMT1HPRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | ITPA, ZC3HAV1, MTAP | FGFR1 4874/4885STING1 17/4885EP300 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.